GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Beneish M-Score

BeiGene (HKSE:06160) Beneish M-Score : -2.19 (As of Apr. 21, 2025)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.19 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for BeiGene's Beneish M-Score or its related term are showing as below:

HKSE:06160' s Beneish M-Score Range Over the Past 10 Years
Min: -7.13   Med: -2.24   Max: 195.87
Current: -2.19

During the past 12 years, the highest Beneish M-Score of BeiGene was 195.87. The lowest was -7.13. And the median was -2.24.


BeiGene Beneish M-Score Historical Data

The historical data trend for BeiGene's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Beneish M-Score Chart

BeiGene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.95 0.52 -3.12 -1.71 -2.19

BeiGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.71 -2.20 -1.97 -2.36 -2.19

Competitive Comparison of BeiGene's Beneish M-Score

For the Biotechnology subindustry, BeiGene's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BeiGene's Beneish M-Score falls into.


;
;

BeiGene Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of BeiGene for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1552+0.528 * 1.0017+0.404 * 1.2586+0.892 * 1.5434+0.115 * 0.6319
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7839+4.679 * -0.083087-0.327 * 1.1716
=-2.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was HK$5,512 Mil.
Revenue was 8767.027 + 7803.458 + 7256.786 + 5880.174 = HK$29,707 Mil.
Gross Profit was 7518.93 + 6475.388 + 6177.976 + 4902.807 = HK$25,075 Mil.
Total Current Assets was HK$31,028 Mil.
Total Assets was HK$46,026 Mil.
Property, Plant and Equipment(Net PPE) was HK$12,882 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$1,339 Mil.
Selling, General, & Admin. Expense(SGA) was HK$14,279 Mil.
Total Current Liabilities was HK$17,217 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,638 Mil.
Net Income was -1180.632 + -945.438 + -940.363 + -1964.746 = HK$-5,031 Mil.
Non Operating Income was -106.76 + 88.179 + -93.595 + 13.784 = HK$-98 Mil.
Cash Flow from Operations was 584.249 + 1467.583 + -746.542 + -2413.959 = HK$-1,109 Mil.
Total Receivables was HK$3,092 Mil.
Revenue was 4954.607 + 6116.47 + 4662.679 + 3514.656 = HK$19,248 Mil.
Gross Profit was 4128.081 + 5362.515 + 3910.79 + 2872.718 = HK$16,274 Mil.
Total Current Assets was HK$32,828 Mil.
Total Assets was HK$45,338 Mil.
Property, Plant and Equipment(Net PPE) was HK$10,855 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$686 Mil.
Selling, General, & Admin. Expense(SGA) was HK$11,803 Mil.
Total Current Liabilities was HK$14,137 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,717 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5512.165 / 29707.445) / (3091.79 / 19248.412)
=0.185548 / 0.160626
=1.1552

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(16274.104 / 19248.412) / (25075.101 / 29707.445)
=0.845478 / 0.844068
=1.0017

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (31028.249 + 12882.374) / 46025.602) / (1 - (32827.823 + 10854.919) / 45338.037)
=0.045952 / 0.03651
=1.2586

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=29707.445 / 19248.412
=1.5434

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(686.423 / (686.423 + 10854.919)) / (1338.596 / (1338.596 + 12882.374))
=0.059475 / 0.094128
=0.6319

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(14278.982 / 29707.445) / (11803.039 / 19248.412)
=0.480653 / 0.613195
=0.7839

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1638.33 + 17217.296) / 46025.602) / ((1717.133 + 14136.621) / 45338.037)
=0.409677 / 0.349679
=1.1716

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-5031.179 - -98.392 - -1108.669) / 46025.602
=-0.083087

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

BeiGene has a M-score of -2.20 suggests that the company is unlikely to be a manipulator.


BeiGene Beneish M-Score Related Terms

Thank you for viewing the detailed overview of BeiGene's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Traded in Other Exchanges
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Executives
Jpmorgan Chase & Co. 2502 Approved lending agent
Oyler John Victor 2101 Beneficial owner
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Baker Brothers Life Sciences Capital, L.p. 2201 Interest of corporation controlled by you
Baker Felix James 2201 Interest of corporation controlled by you
Baker Julian Charles 2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc 2201 Interest of corporation controlled by you
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Amgen Inc. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene Headlines

No Headlines